Process patent legislation
Rep. Moorhead (R-Calif.) on Feb. 7 introduced a bill which makes it patent infringement to import, use, or sell in the U.S. products, including drugs, made by a patented process; exempts from damages infringers other than mfrs. who lack knowledge or notice of infringement; and places on alleged infringers the burden of proving products in question are not produced by the patented process. The bill applies to goods produced or imported after enactment. A similar bill introduced last year passed the Senate after pharmaceuticals were exempted. Congress adjourned before it was reconciled with a House-passed version
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.